5-Minute Journal Club — SABCS 2010 Presentations


Please click each issue for edition topic links.

San Antonio Highlights: When Should Patients with Metastatic Breast Cancer Be Rebiopsied? And More... Issue 8 — March 21, 2011 — Current Edition

Go directly to our slides and commentary on:

Discordance in Hormone Receptor and HER2 Status in Breast Cancer During Tumor Progression

Efficacy of Denosumab vs Zoledronic Acid in Patients with BC and Bone Mets and Safety Analysis of Bev Plus Bisphosphonates in Met BC

Management of Aromatase Inhibitor (AI)-Pretreated Advanced Breast Cancer

Efficacy and Safety of Bevacizumab-Containing Chemotherapy Regimens in Metastatic Breast Cancer

San Antonio Highlights: Another Uninspiring Year for Adjuvant Therapy of HER2-Negative Breast Cancer Issue 7 — March 11, 2011

Go directly to our slides and commentary on:

Effect of Number of Treatment Cycles of Adjuvant Chemotherapy on Clinical Outcomes

The Efficacy of Adjuvant Capecitabine-Containing Regimens in Medium- to High-Risk Breast Cancer

The Efficacy of (Neo)Adjuvant Capecitabine-Containing Regimens in High-Risk Breast Cancer

CIBOMA/2004-01/GEICAM 2003-11: Adjuvant Capecitabine Maintenance Therapy for Triple-Negative Early Breast Cancer

Safety Analysis of Bevacizumab-Containing Adjuvant Chemotherapy in a Phase II Pilot Trial

SABCS Highlights: More on the Management of Patients with HER2-Positive Tumors
Issue 6 — March 1, 2011

Go directly to our slides and commentary on:

Concordance of HER2 Testing in Breast Cancer

The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer

Efficacy of HER2-Based Therapy in Patients After Failure of Prior T-DM1 Therapy and the Evaluation of an Anti-HER2 Combination Regimen

Capecitabine (Seven On, Seven Off) with Lapatinib for Metastatic Breast Cancer Refractory to Trastuzumab

CYP2D6 Takes Two More Shots to the Head... and More on Endocrine/Metabolic Issue in BC Issue 5 — February 15, 2011

Go directly to our slides and commentary on:

Correlation between Tamoxifen-Metabolizing Enzymes Genotypes/Phenotypes and Clinical Outcomes in Patients with Breast Cancer Treated with Tamoxifen

Fulvestrant 500 mg or Anastrozole as First-Line Treatment in Advanced Breast Cancer

A Prospective and Retrospective Registry of Pregnant Patients with Breast Cancer

The Effect of Obesity on Treatment Outcomes in Patients with Breast Cancer

More from SABCS — Genomic Predictors of Benefit from Adjuvant Chemotherapy
Issue 4 — February 8, 2011


Go directly to our slides and commentary on:

Predicting Chemotherapy Benefit in Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score® (RS) or the Recurrence Score-Pathology-Clinical (RSPC) Tool

Meta-Analysis of the Effect of the Oncotype DX® Assay Recurrence Score® (RS) on Clinical Decision-Making

Prognostic Value of Genomic Analysis After Neoadjuvant Chemotherapy for Breast Cancer

SABCS Highlights: BRCA, PARP Inhibitors and Triple-Negative Breast Cancer
Issue 3 — January 26, 2011


Go directly to our slides and commentary on:

Phase III Study and Meta-Analysis Results with Bevacizumab and First-Line Chemotherapy for Metastatic Breast Cancer (mBC)

Preclinical and Clinical Proof-of-Concept Studies of PARP Inhibitors with or without DNA-Damaging Chemotherapeutic Agents for Triple-Negative Breast Cancer

EGFR Inhibition with Cetuximab in Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)

The Door Closes (for Now) on Adjuvant Bisphosphonates
Issue 2 — January 18, 2011


Go directly to our slides and commentary on:

(Neo)Adjuvant Treatment with or without Zoledronic Acid for Stage II or III Breast Cancer

Long-Term Data from the ABCSG-12 Trial of Adjuvant Zoledronic Acid and Endocrine Therapy

ZO-FAST Study of the Effect of Zoledronic Acid on Aromatase Inhibitor-Associated Bone Loss in Early Breast Cancer

SABCS Highlights: A Trio of Landmark Neoadjuvant HER2-Positive Trials
Issue 1 — January 13, 2011


Go directly to our slides and commentary on:

Trastuzumab or Lapatinib with Neoadjuvant Chemotherapy in the Management of Previously Untreated HER2-Positive Primary Breast Cancer

First Results of the NeoALTTO (BIG 01-06/EGF 106903) Neoadjuvant Study of Lapatinib, Trastuzumab or the Combination and Paclitaxel for Women with HER2-Positive Primary Breast Cancer

Combination of Trastuzumab, Pertuzumab and Docetaxel as Neoadjuvant Therapy in the Management of Previously Untreated HER2-Positive Early, Locally Advanced and Inflammatory Breast Cancer

Neoadjuvant Trastuzumab and Chemotherapy in the Management of Previously Untreated HER2-Positive Primary Breast Cancer